We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Aurinia Pharmaceuticals Inc is a biotechnology business with stocks listed in the US. Aurinia Pharmaceuticals shares (AUPH) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$28 – an increase of 36.12% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | US$9.72 - US$24.18 |
|---|---|
| 50-day moving average | US$21.1197 |
| 200-day moving average | US$15.0965 |
| Target price | US$28.33 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$-1.17 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $28
| 1 week (2021-10-14) | 33.08% |
|---|---|
| 1 month (2021-09-24) | 20.48% |
| 3 months (2021-07-23) | 146.70% |
| 6 months (2021-04-23) | 124.18% |
| 1 year (2020-10-23) | 78.80% |
|---|---|
| 2 years (2019-10-24) | 479.71% |
| 3 years (2018-10-24) | 451.18% |
| 5 years (2016-10-24) | 662.94% |
| Revenue TTM | US$57.6 million |
|---|---|
| Gross profit TTM | US$-209,000 |
| Return on assets TTM | -27.15% |
| Return on equity TTM | -51.67% |
| Profit margin | -256.27% |
| Book value | 2.588 |
| Market capitalisation | US$3.6 billion |
TTM: trailing 12 months
There are currently 18.2 million Aurinia Pharmaceuticals shares held short by investors – that's known as Aurinia Pharmaceuticals's "short interest". This figure is 2.4% down from 18.7 million last month.
There are a few different ways that this level of interest in shorting Aurinia Pharmaceuticals shares can be evaluated.
Aurinia Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Aurinia Pharmaceuticals shares currently shorted divided by the average quantity of Aurinia Pharmaceuticals shares traded daily (recently around 4.2 million). Aurinia Pharmaceuticals's SIR currently stands at 4.39. In other words for every 100,000 Aurinia Pharmaceuticals shares traded daily on the market, roughly 4390 shares are currently held short.
However Aurinia Pharmaceuticals's short interest can also be evaluated against the total number of Aurinia Pharmaceuticals shares, or, against the total number of tradable Aurinia Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aurinia Pharmaceuticals's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Aurinia Pharmaceuticals shares in existence, roughly 140 shares are currently held short) or 0.1426% of the tradable shares (for every 100,000 tradable Aurinia Pharmaceuticals shares, roughly 143 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aurinia Pharmaceuticals.
Find out more about how you can short Aurinia Pharmaceuticals stock.
We're not expecting Aurinia Pharmaceuticals to pay a dividend over the next 12 months.
Aurinia Pharmaceuticals's shares were split on a 1:50 basis on 22 October 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aurinia Pharmaceuticals shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Aurinia Pharmaceuticals shares which in turn could have impacted Aurinia Pharmaceuticals's share price.
Over the last 12 months, Aurinia Pharmaceuticals's shares have ranged in value from as little as US$9.72 up to US$24.18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aurinia Pharmaceuticals's is 0.3646. This would suggest that Aurinia Pharmaceuticals's shares are less volatile than average (for this exchange).
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Shares in the wealth management giant have been largely stable in the last 6 months.
Everything we know about the Judo Capital Holdings IPO, plus information on how to buy in.
Everything we know about the Alloggio Group IPO, plus information on how to buy in.
Everything we know about the Larvotto Resources IPO, plus information on how to buy in.
Everything we know about the Vulcan Steel IPO, plus information on how to buy in.
Everything we know about the Artrya IPO, plus information on how to buy in.
Everything we know about the 8 Au IPO, plus information on how to buy in.
Everything we know about the Radiopharm Theranostics IPO, plus information on how to buy in.
The online retailer’s shares have lost more than half their value in the last 12 months.
